Flash Finance

Alembic Pharmaceuticals LimitedAPLLTDCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹789.45
MCap ₹15,518 Cr · P/E 22.4
Alembic Pharmaceuticals Limited — Stock analysis & AI research Alembic Pharmaceuticals Limited — Seasonality — best & worst months Alembic Pharmaceuticals Limited — Technical indicators & charts Alembic Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Alembic Pharmaceuticals Limited — Double Bottom pattern forming Alembic Pharmaceuticals Limited — Live exchange announcements
📋 Stocks Cheaper Than Their Industry📋 High Promoter Holding Stocks📋 Small Cap Stocks List 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,150 Cr
Sales · Jun 2026
+25.7% YoY
₹332 Cr
Operating Profit · Jun 2026
+18.0% YoY
15.4%
OPM % · Jun 2026
-6.1% YoY
₹173 Cr
Net Profit · Jun 2026
+12.7% YoY
₹8.80
EPS · Jun 2026
+12.1% YoY

📝 Alembic Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Alembic Pharmaceuticals Limited reported revenue of ₹2,150 crore for the quarter ended June 2026 (Q1 FY27), up 25.7% from ₹1,711 crore in the same quarter last year, and up 16.3% sequentially over the March 2026 quarter.

Net profit rose 12.7% year-on-year to ₹173 crore, from ₹154 crore. Earnings per share (EPS) came in at ₹8.80.

Operating profit stood at ₹332 crore — an operating margin (OPM) of 15.4%, compared with 16.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Alembic Pharmaceuticals Limited posted revenue of ₹7,345 crore, a growth of 10.1% over FY25, with a net profit of ₹672 crore (up 15.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹7,784 crore with a net profit of ₹692 crore.

Valuation snapshot

At the current price of ₹789.45, APLLTD has a market capitalisation of ₹15,518 crore and a trailing P/E of about 22.4.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 69.74%, foreign institutional investors (FIIs) 4.26%, domestic institutional investors (DIIs) 16.17%, public shareholders 9.83% of Alembic Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹15,518 Cr
Current Price ?
₹789.5
P/E ?
22.43below ind
Industry P/E ?
35.00
P/B ?
2.73
P/S ?
1.99
P/FCF ?
53.51
Enterprise Value ?
₹16,948 Cr
EV/EBITDA ?
14.52
PEG ?
0.80
Earnings Yield ?
4.9%
Dividend Yield ?
1.39%
Profitability & Returns
Sales (TTM) ?
₹7,784 Cr
OPM ?
15.0%
Profit after tax (TTM) ?
₹692 Cr
EPS (TTM) ?
₹35.19
ROCE ?
13.0%
ROE ?
12.2%
ROA ?
7.9%
Growth
Sales — latest qtr ?
₹2,150 Cr
PAT — latest qtr ?
₹173 Cr
YoY qtr sales growth ?
25.7%
YoY qtr profit growth ?
12.7%
Sales growth (3y) ?
9%
Sales growth (5y) ?
6%
Profit growth (3y) ?
28%
Profit growth (5y) ?
-9%
Financial Health
Debt ?
₹1,430 Cr
Debt to Equity ?
0.25
Interest Coverage ?
8.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
69.74%
Change in promoter holding ?
0.06%
Pledged percentage ?
N/A
Market
Return 3 months ?
-4.3%
Return 6 months ?
0.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,5091,4061,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,8761,8482,150 +25.7% +16.3%
Operating Profit 249212199208266260237239260272281316292228332 +18.0% +45.6%
Other Income 01121034217101467-27215 +129.7% +646.5%
Interest 151414161511131922252424232328 +17.4% +20.0%
Depreciation 677466686969697170697476808998 +32.5% +9.8%
Profit Before Tax 154116130135185183157180178192190224162119222 +16.7% +86.4%
Net Profit 122153121137180178135153138157154185132202173 +12.7% -14.3%
EPS 6.207.766.146.959.189.076.847.797.017.987.859.406.7610.318.80 +12.1% -14.6%
OPM % 16.5% 15.1% 13.4% 13.1% 16.3% 17.1% 15.2% 14.5% 15.4% 15.4% 16.4% 16.5% 15.6% 12.3% 15.4% -6.1% +25.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹6,672 Cr ₹7,345 Cr ₹7,784 Cr +10.1%
Operating Profit ₹1,008 Cr ₹1,117 Cr ₹1,168 Cr +10.8%
OPM % 15.11% 15.21% 15.00% +0.7%
NPM % 8.73% 9.15% 8.89% +4.8%
Other Income ₹43 Cr ₹-12 Cr ₹-3 Cr -127.3%
Depreciation ₹279 Cr ₹319 Cr ₹343 Cr +14.5%
Interest ₹79 Cr ₹94 Cr ₹98 Cr +19.0%
EBIT ₹730 Cr ₹798 Cr ₹825 Cr +9.4%
PBT ₹707 Cr ₹695 Cr ₹727 Cr -1.7%
Tax ₹126 Cr ₹76 Cr ₹90 Cr -39.1%
Net Profit ₹583 Cr ₹672 Cr ₹692 Cr +15.4%
EPS ₹29.62 ₹34.32 ₹35.27 +15.9%
Material Cost ₹2,083 Cr ₹1,130 Cr ₹1,228 Cr -45.7%
Employee Cost ₹1,562 Cr ₹860 Cr ₹911 Cr -44.9%
Extraordinary Items ₹13 Cr — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 39393939 +0.0%
Reserves 4,3314,7795,1525,636 +9.4%
Borrowings 7225131,2581,430 +13.7%
Other Liabilities 1,0901,1141,3241,658 +25.2%
Total Liabilities 6,1836,4467,7738,763 +12.7%
Fixed Assets 2,3982,5472,5243,130 +24.0%
CWIP 601524837634 -24.3%
Investments 9693127141 +11.0%
Other Assets 3,0873,2814,2854,858 +13.4%
Total Assets 6,1836,4467,7738,763 +12.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 72480388783 +789.8%
Cash from Investing Activity -448-321-568-506 +10.9%
Cash from Financing Activity -262-438444-164 -136.9%
Net Cash Flow 1445-37113 +405.4%
Free Cash Flow 282487-466290 +162.2%
CFO/OP 115%88%16%79% +393.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 68607773 -5.2%
Inventory Days 315350466462 -0.9%
Days Payable 145157179154 -14.0%
Cash Conversion Cycle 237253363381 +5.0%
Working Capital Days 77888788 +1.1%
ROCE % 7%13%13%13% +0.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 69.68%69.74%69.74%69.74% +0.0%
FIIs 3.96%4.04%4.23%4.26% +0.7%
DIIs 16.46%16.30%16.17%16.17% +0.0%
Public 9.91%9.92%9.84%9.83% -0.1%
No. of Shareholders 89,01389,96987,00086,432 -0.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 APLLTD Alembic Pharmaceuticals ₹792.00 15,568 22.5 7,784 692 15.0% 8.9% 10.1% 15.4% 25.7% 12.7%
❓ Frequently asked questions
What was Alembic Pharmaceuticals Limited's revenue in Q1 FY27?
Alembic Pharmaceuticals Limited reported revenue of ₹2,150 crore for the quarter ended June 2026 (Q1 FY27), up 25.7% from ₹1,711 crore in the same quarter last year, and up 16.3% sequentially over the March 2026 quarter.
What was Alembic Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 12.7% year-on-year to ₹173 crore, from ₹154 crore. Earnings per share (EPS) came in at ₹8.80.
What is APLLTD's market capitalisation and P/E ratio?
At the current price of ₹789.45, APLLTD has a market capitalisation of ₹15,518 crore and a trailing P/E of about 22.4.
Who owns Alembic Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 69.74%, foreign institutional investors (FIIs) 4.26%, domestic institutional investors (DIIs) 16.17%, public shareholders 9.83% of Alembic Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI